Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional)
ID: 353853Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353853

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-185.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 29, 2024 12:00 AM
  4. 4
    Due Aug 13, 2024 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional)". This grant aims to support research that enhances the capacity, transformation, and scalability of HIV testing, prevention, and care services provided by pharmacists and pharmacies in both US and global settings. The goal is to develop training curricula that enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver a comprehensive range of HIV services with ease, equity, and effectiveness. The grant utilizes the R01 grant mechanism, while the RFA-MH-25-186 utilizes the R21 mechanism. Projects that lack preliminary data or propose to pilot a novel intervention may be more suitable for the R21 mechanism, while applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for applications is August 13, 2024. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-185.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
No associated files provided.
Similar Opportunities
Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)". This grant aims to support research that enhances the capacity, transformation, and scalability of HIV testing, prevention, and care services provided by pharmacists and pharmacies in both US and global settings. The goal is to develop training curricula that enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver a comprehensive range of HIV services with ease, equity, and effectiveness. The R21 grant mechanism will be used for projects that lack preliminary data or propose to pilot a novel intervention. On the other hand, projects with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The close date for this grant opportunity is August 13, 2024. For more information and to apply, visit the following link: [Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)](http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-186.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)". This grant aims to support high priority research at the intersection of HIV and substance use. The funding is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. The purpose of this grant is to invite innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment, and cure of HIV among people who use drugs (PWUD). The applicants are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. The grant does not require cost sharing or matching requirements. The funding instrument type is a grant, and the category of funding activity is health. The maximum award ceiling for this grant is $1,500,000. Eligible applicants for this grant include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the federal government, faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. territories or possessions. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. The closing date for this grant opportunity is February 11, 2027. The archive date is March 19, 2027. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-060.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-060.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)". This grant aims to support innovative research that focuses on optimizing HIV prevention and care, in line with the priorities of the NIMH Division of AIDS Research (DAR). The grant encourages applications that involve formative basic behavioral and social science to better understand steps in the HIV prevention or care continuum, as well as the development and pilot testing of innovative intervention approaches. For more information about the research priorities, applicants are encouraged to refer to the current Notices of Special Interests (NOSIs) from NIMH DAR. The grant does not require cost sharing or matching and is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, non-domestic entities, regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The grant has a closing date of January 9, 2026, and an award ceiling of $275,000. For further information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-23-061.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-061.html).
Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)". This grant aims to support multilevel and multidisciplinary intervention research to improve the quality of life and promote successful aging among people with HIV who have HIV-associated non-AIDS comorbidities. The focus is on individuals from racial and ethnic backgrounds and lower socioeconomic status groups. The grant does not require cost sharing or matching. The funding instrument type is a grant, and the category of funding activity is health. The opportunity is posted under the discretionary category. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and Historically Black Colleges and Universities (HBCUs). Non-domestic (non-U.S.) entities and components are not eligible to apply. The closing date for this grant opportunity is December 11, 2026. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-003.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-003.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)". This grant aims to support research focused on suppressing the transcriptional activity of HIV in individuals with substance use disorders (SUD) and HIV infection. The goal is to identify targets and pathways to suppress HIV transcription in HIV reservoirs, including the central nervous system (CNS), and to discover novel compounds that can be used as pharmacological probes and drugs to suppress HIV transcription in individuals with HIV-SUD comorbidity. The grant does not require cost sharing or matching. The maximum award ceiling is $400,000. Other eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for applications is August 13, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-007.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-007.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.